Programmed Death Ligand-1-directed Antibody Interactions [MoA] - N0000193336
Pharmacologic Class Information
Pharmacologic Code | N0000193336 |
Pharmacologic Name | Programmed Death Ligand-1-directed Antibody Interactions |
Pharmacologic Uses |
|
Pharmacologic Concept | Mechanisms of Action - [MoA] |
Pharmacologic Concept Description | This concept refers to the mechanism of action pharmacologic action at the receptor, membrane, or tissue level. In MED-RT, molecular, subcellular, or cellular effects of drug generic ingredients, organized into a chemical function classification hierarchy, beneath the "Cellular or Molecular Interactions" concept. |
NDC Products with Programmed Death Ligand-1-directed Antibody Interactions
The table contains 3 products whose active ingredient are classified under the same pharmacologic class Programmed Death Ligand-1-directed Antibody Interactions [MoA].
NDC | Proprietary Name | Non-Proprietary Name | Dosage Form | Route Name | Company Name | Status | |
---|---|---|---|---|---|---|---|
0310-4500 | Imfinzi | Non-Proprietary Name: Durvalumab | Injection, Solution | Intravenous | Astrazeneca Pharmaceuticals Lp | ACTIVE | |
0310-4611 | Imfinzi | Non-Proprietary Name: Durvalumab | Injection, Solution | Intravenous | Astrazeneca Pharmaceuticals Lp | ACTIVE | |
44087-3535 | Bavencio | Non-Proprietary Name: Avelumab | Injection, Solution, Concentrate | Intravenous | Emd Serono, Inc. | ACTIVE |